Zydelig
Zydelig ingredients
| Active ingredient | Strength |
|---|---|
| Idelalisib | 100 mg/1, 150 mg/1 |
What Zydelig is used for
The FDA lists the approved uses on the official label (below). In the EU, idelalisib is approved as Zydelig for:
Zydelig is indicated in combination with an anti-CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies. Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Zydelig
- Generic name
- Idelalisib
- Made by
- Gilead Sciences, Inc.
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA205858
- On the US market since
- 2014
Official information
- MedlinePlus drug information (search for Idelalisib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zydelig?
Zydelig (Idelalisib) is a cancer medicine made by Gilead Sciences, Inc., approved by the US FDA.
What are the ingredients of Zydelig?
Zydelig contains Idelalisib (100 mg/1, 150 mg/1).
Is Zydelig approved in Europe?
The same active substance is approved in the EU as Zydelig.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA